{"id":"W2105518844","doi":"10.1016/j.lungcan.2010.05.022","title":"A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Center for Research Resources; National Cancer Institute; Bayer Canada; Eli Lilly and Company","keywords":"Medicine; Sorafenib; Carboplatin; Pemetrexed; Internal medicine; Etoposide; Oncology; Refractory (planetary science); Lung cancer; Cisplatin; Urology; Chemotherapy; Hepatocellular carcinoma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001800334,0.002138079,0.003155963,0.0005935831,0.0006809151,0.001295629,0.001089766,0.001554385,0.005862617],"category_scores_gemma":[0.001410997,0.0008230331,0.002674775,0.0005727286,0.001498434,0.001553604,0.0005388568,0.004889515,0.001192952],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001300916,"about_ca_system_score_gemma":0.002084454,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001895484,"about_ca_topic_score_gemma":0.004495978,"domain_scores_codex":[0.9993957,0.0003054594,0.00002836383,0.0001076313,0.00003102299,0.0001318665],"domain_scores_gemma":[0.9989147,0.000201,0.0001324461,0.00008034797,0.00004812048,0.0006234015],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9286229,0.02154711,0.001397249,0.0005313532,0.001304585,0.0001384511,0.0001746056,0.001587331,0.009244852,0.0002267965,0.002778978,0.03244581],"study_design_scores_gemma":[0.852589,0.142704,0.002056007,0.00001781151,0.0003425875,0.00008422614,0.0000459348,0.0003785645,0.0007412364,0.000110438,0.0009152278,0.00001491256],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909637,0.002594555,0.0003881372,0.001220281,0.0003540994,0.001604226,0.0009315159,0.00009371826,0.001849796],"genre_scores_gemma":[0.9877643,0.002544769,0.00133155,0.001022169,0.0003082452,0.001838847,0.002149137,0.00004407732,0.002996826],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005862617,"threshold_uncertainty_score":0.01961243,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01762870376819342,"score_gpt":0.3877932423721357,"score_spread":0.3701645386039423,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}